27 studies found for:    poly iclc | Open Studies
Show Display Options
Rank Status Study
1 Recruiting In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Conditions: Melanoma;   Head and Neck Cancer;   Sarcoma;   Non-Melanoma Skin Cancers
Intervention: Biological: Hiltonol
2 Recruiting A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Condition: Brain Tumors
Intervention: Drug: Poly ICLC
3 Not yet recruiting Pembrolizumab + Poly-ICLC in MRP Colon Cancer
Conditions: Metastatic Colon Cancer;   Solid Tumor
Interventions: Drug: pembrolizumab;   Drug: Poly-ICLC
4 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Conditions: Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Epacadostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Poly ICLC
5 Recruiting In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Condition: Low-Grade B-cell Lymphoma
Interventions: Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
6 Not yet recruiting A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Conditions: Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC
7 Not yet recruiting A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Conditions: Non Small Cell Lung Cancer;   Advanced Triple Negative Breast Cancer;   Small Cell Lung Cancer;   Urothelial Cancer;   Mesothelioma;   Malignant Melanoma
Interventions: Drug: Pembrolizumab;   Biological: CDX-1401;   Biological: Poly-ICLC
8 Recruiting Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Solid Tumors
Condition: Solid Tumors
Interventions: Biological: Peptides;   Drug: Poly-ICLC
9 Recruiting Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
Condition: Neoplasms
Interventions: Biological: Hiltonol and autologous dendritic cells;   Radiation: Hiltonol, dendritic cells and radiation
10 Recruiting A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Conditions: Newly Diagnosed Pediatric Pontine Glioma.;   Newly Diagnosed Pediatric High Grade Glioma.;   Recurrent Pediatric High Grade Glioma.;   Recurrent Pediatric Low Grade Glioma.
Interventions: Biological: HLA-A2 restricted glioma antigen peptides vaccine;   Biological: Poly-ICLC
11 Recruiting Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Montanide ISA-51;   Drug: polyICLC;   Drug: Cyclophosphamide
12 Recruiting A Vaccine Trial for Low Grade Gliomas
Condition: Low Grade Glioma
Intervention: Biological: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
13 Recruiting Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma Multiforme;   Astrocytoma, Grade IV
Interventions: Biological: Personalized peptide vaccine;   Drug: Poly-ICLC;   Drug: Temozolomide
14 Not yet recruiting A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
Conditions: Glioblastoma;   Glioma
Interventions: Drug: Bevacizumab;   Biological: Peptide Vaccine;   Drug: Poly-ICLC as immune adjuvant;   Drug: Keyhole limpet hemocyanin (KLH)
15 Recruiting Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Poly ICLC;   Radiation: Focal lesional radiation
16 Recruiting A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Condition: Melanoma
Interventions: Biological: DC Vaccine;   Biological: Montanide Vaccine;   Biological: Poly-ICLC
17 Recruiting Autologous OC-L Vaccine and Ovarian Cancer
Conditions: Primary Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: OC-L;   Other: Montanide;   Other: poly-ICLC (Hiltonol),
18 Not yet recruiting Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Condition: Glioma - Recurrent Grade II
Intervention: Biological: GBM6-AD and poly-ICLC
19 Recruiting Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Conditions: Melanoma;   Metastatic Melanoma;   Mucosal Melanoma
Interventions: Biological: Peptide Vaccine (LPV7) + Tetanus peptide;   Other: PolyICLC;   Other: Resiquimod;   Other: IFA
20 Recruiting Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Glioblastoma Multiforme
Interventions: Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose);   Drug: Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Indicates status has not been verified in more than two years